177Lu-PSMA-I&T Safe, Active in Heavily Treated Patients With mCRPC

Share this content:
Rigoligand therapy with a beta-emitting 177Lu-PSMA-I&T appeared to be safe and active in heavily treated in prostate cancer.
Rigoligand therapy with a beta-emitting 177Lu-PSMA-I&T appeared to be safe and active in heavily treated in prostate cancer.

Rigoligand therapy with a beta-emitting 177Lutetium-labeled prostate-specific membrane antigen-ligand (177Lu-PSMA-I&T) appeared to be safe and active in heavily treated patients with metastatic castration-resistant prostate cancer (mCRPC), according to a study published in The Journal of Urology.1

Patients with mCRPC who failed treatment with both chemotherapy and novel androgen-receptor targeted therapy were treated 8-weekly with up to 4 cycles of 177Lu-PSMA-I&T.

The first 3 patients were treated with a lower activity of 3.7 GBq in their first cycle and had a favorable safety profile. In 19 subsequent patients, the activity was raised to 7.4 GBq and a total of 40 cycles were completed. 

No grade 3/4 toxicities occurred with the high activity regimen. The most common grade 1/2 toxicities were dry mouth in 7 patients (37%), anemia in 6 patients (32%), and thrombopenia in 5 patients (25%).

A maximum prostate-specific antigen decline of ≥ 30%, ≥ 50%, and ≥ 90% occurred in 56%, 33%, and 11% of patients, respectively.

RELATED: Late Toxicity More Common With Hypofractionated RT in Prostate Cancer

Combined assessment of bone and soft-tissue metastases showed that 5% of patients achieved complete remission, 63% of patients achieved stable disease, and 32% of patients experienced progressive disease.

Eastern Cooperative Oncology group status improved or remained stable in 74% of patients.

Reference

  1. Heck MM, Retz M, D'Alessandria C, et al. Systemic radioligand therapy with 177LU-PSMA-I&T in patients with metastatic castration-resistant prostate cancer [published online ahead of print March 7, 2016]. J Urol. doi: 10.1016/j.juro.2016.02.2969.   

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs